363 related articles for article (PubMed ID: 11156212)
1. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
Feldman AL; Tamarkin L; Paciotti GF; Simpson BW; Linehan WM; Yang JC; Fogler WE; Turner EM; Alexander HR; Libutti SK
Clin Cancer Res; 2000 Dec; 6(12):4628-34. PubMed ID: 11156212
[TBL] [Abstract][Full Text] [Related]
2. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma.
Feldman AL; Alexander HR; Yang JC; Linehan WM; Eyler RA; Miller MS; Steinberg SM; Libutti SK
Cancer; 2002 Oct; 95(8):1637-43. PubMed ID: 12365010
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
Bono P; Teerenhovi L; Joensuu H
Cancer; 2003 Jun; 97(11):2767-75. PubMed ID: 12767089
[TBL] [Abstract][Full Text] [Related]
5. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma.
Dhar DK; Ono T; Yamanoi A; Soda Y; Yamaguchi E; Rahman MA; Kohno H; Nagasue N
Cancer; 2002 Nov; 95(10):2188-95. PubMed ID: 12412173
[TBL] [Abstract][Full Text] [Related]
6. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
7. Serum endostatin levels in patients with epithelial ovarian cancer.
Hata K; Dhar DK; Kanasaki H; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Nagasue N; Miyazaki K
Anticancer Res; 2003; 23(2C):1907-12. PubMed ID: 12820477
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of vascular endothelial growth factor, basic fibroblast growth factor and endostatin in human metastatic liver tumors.
Miyashita M; Tajiri T; Yanagi K; Shimizu T; Futami R; Sasajima K; Tokunaga A
Hepatogastroenterology; 2003; 50(50):308-9. PubMed ID: 12749209
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
[TBL] [Abstract][Full Text] [Related]
10. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
Shang ZJ; Li JR; Li ZB
Int J Oral Maxillofac Surg; 2002 Oct; 31(5):495-8. PubMed ID: 12418564
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of vascular endothelial growth factor in vulvar cancer.
Hefler L; Tempfer C; Obermair A; Frischmuth K; Sliutz G; Reinthaller A; Leodolter S; Kainz C
Clin Cancer Res; 1999 Oct; 5(10):2806-9. PubMed ID: 10537345
[TBL] [Abstract][Full Text] [Related]
12. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1.
Lissoni P; Malugani F; Bonfanti A; Bucovec R; Secondino S; Brivio F; Ferrari-Bravo A; Ferrante R; Vigoré L; Rovelli F; Mandalà M; Viviani S; Fumagalli L; Gardani GS
J Biol Regul Homeost Agents; 2001; 15(2):140-4. PubMed ID: 11501971
[TBL] [Abstract][Full Text] [Related]
13. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis.
Nagashima M; Asano G; Yoshino S
J Rheumatol; 2000 Oct; 27(10):2339-42. PubMed ID: 11036826
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
15. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer.
McDonnell CO; Harmey JH; Bouchier-Hayes DJ; Walsh TN
Br J Surg; 2001 Aug; 88(8):1105-9. PubMed ID: 11488797
[TBL] [Abstract][Full Text] [Related]
16. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.
Coskun U; Günel N; Toruner FB; Sancak B; Onuk E; Bayram O; Cengiz O; Yilmaz E; Elbeg S; Ozkan S
Neoplasma; 2003; 50(1):41-6. PubMed ID: 12687277
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors].
Peng XP; Li JD; Li MD; Ye XM; Yan WC
Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072
[TBL] [Abstract][Full Text] [Related]
18. Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma.
Balsari A; Maier JA; Colnaghi MI; Ménard S
Lab Invest; 1999 Jul; 79(7):897-902. PubMed ID: 10418830
[TBL] [Abstract][Full Text] [Related]
19. Serum endostatin levels are elevated in patients with soft tissue sarcoma.
Feldman AL; Pak H; Yang JC; Alexander HR; Libutti SK
Cancer; 2001 Apr; 91(8):1525-9. PubMed ID: 11301401
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic activity of melatonin in advanced cancer patients.
Lissoni P; Rovelli F; Malugani F; Bucovec R; Conti A; Maestroni GJ
Neuro Endocrinol Lett; 2001; 22(1):45-7. PubMed ID: 11335879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
